Is there any relationship between plasma antioxidant capacity and lung function in smokers and in patients with chronic obstructive pulmonary disease?

Irfan Rahman, Elzbieta Swarska, Michael Henry, Jan Stolk, William MacNee

Abstract

Background—It has been suggested that oxidative stress is an important factor in the pathogenesis of chronic obstructive pulmonary disease (COPD). We have shown that an oxidant/antioxidant imbalance occurs in the distal air spaces of smokers and in patients with COPD which is reflected systemically in the plasma. A study was undertaken to determine whether plasma antioxidant status correlated with lung function as assessed by forced expiratory volume in one second (FEV₁) and forced vital capacity (FVC) in smokers and patients with COPD.

Methods—Plasma antioxidant capacity, assessed by the Trolox equivalent antioxidant capacity (TEAC) as an index of overall systemic oxidative stress, and protein thiol levels were measured in 95 patients with stable COPD, in 82 healthy smokers, and in 37 healthy non-smokers.

Results—Mean (SE) plasma TEAC levels were significantly decreased in patients with COPD (0.81 (0.03) mmol/l, p<0.001) and in healthy smokers (0.87 (0.04) mmol/l, p<0.001) compared with healthy non-smokers (1.31 (0.11) mmol/l). The mean differences in plasma antioxidant capacity (mM) were (0.81, 95% confidence interval (CI) 0.22 to 1.48), (0.87, 95% CI 0.2 to 1.46), and (1.31, 95% CI 1.09 to 1.58) in patients with COPD, healthy smokers, and healthy non-smokers, respectively. This reduction was associated with a 29% (95% CI 18 to 38) and a 30% (95% CI 19 to 40) decrease in plasma protein thiol levels in COPD patients and smokers, respectively. Current smoking was not the main contributor to the reduction in antioxidant capacity in patients with COPD as those patients who were still smokers had similar TEAC levels (mean (SE) 0.78 (0.05); n = 25) to those who had stopped smoking (0.84 (0.02); n = 70). No significant correlations were found between spirometric data measured as FEV₁ % predicted or FEV₁/FVC % predicted and the plasma levels of TEAC in patients with COPD, healthy smokers, or healthy non-smokers. Similarly, there was no significant correlation between FEV₁ % predicted or FEV₁/FVC % predicted and the levels of plasma protein thiols in the three groups.

Conclusions—These data confirm decreased antioxidant capacity in smokers and patients with COPD, indicating the presence of systemic oxidative stress. However, no relationship was found between protein thiols or TEAC levels and measurements of airflow limitation in either smokers or in patients with COPD.

Keywords: oxidants; antioxidants; protein thiols; smoking; chronic obstructive pulmonary disease

Respiratory Medicine Unit, Royal Infirmary, Edinburgh, UK
I Rahman
E Swarska
W MacNee

Department of Medicine and Therapeutics, University College Dublin, Ireland
M Henry

Department of Pulmonology, Leiden University Medical Centre, Leiden, The Netherlands
J Stolk

Correspondence to: Professor W MacNee, ELEGI Colt Research Laboratories, Wilkie Building, Medical School, University of Edinburgh, Edinburgh EH8 9AG, UK

Received 2 March 1999
Returned to authors 4 June 1999
Revised version received 7 December 1999
Accepted for publication 8 December 1999
potentially lead to prediction of which smokers will progress to develop significant disease. In the light of this, we have recently shown that the antioxidant capacity is decreased in the plasma of smokers and of patients with exacerbations of COPD. In addition, there are numerous reports showing decreased levels of plasma antioxidants and increased markers of oxidative stress in the lungs, bronchoalveolar lavage fluid, and plasma of smokers and patients with COPD compared with normal subjects (reviewed by Rahman and MacNee). There is also evidence of increased levels of markers of oxidative stress such as hydrogen peroxide and 8-isoprostane-F2α (an oxidative by product of arachidonic acid) in the exhaled breath of smokers and in patients with COPD. These data suggest that smoking can cause oxidative modification of biomolecules in biological fluids in vivo and thereby impose cell/tissue injury and inflammation, which are the hallmarks of inflammatory lung diseases such as COPD. Epidemiological studies have shown that some of these markers of oxidative stress may be associated with reduced lung function. An example of this is the inverse relationship between circulating neutrophil numbers and the FEV1. In addition, a high dietary intake of the antioxidant vitamins C and E has been shown to relate to better lung function in the general population and to a lower prevalence of chronic bronchitis in smokers, suggesting a protective effect of these vitamins. Shunemann et al have recently reported a negative correlation between plasma lipid peroxides, which are a measure of oxidative stress, and lung function in non-smokers. However, there are conflicting reports available on the association between an oxidant/antioxidant imbalance and lung function in healthy subjects and in smokers.

The purpose of this study was to confirm the hypothesis that an oxidant/antioxidant imbalance occurs in smokers and in patients with COPD and to correlate this with the degree of airflow obstruction. We therefore measured plasma antioxidant capacity and the levels of protein sulphhydrils and correlated these with lung function in healthy non-smokers, healthy smokers, and in patients with COPD. We also examined the effects of smoking and sex differences on the antioxidant capacity in these subjects.

Methods

Patients

Ninety five patients with clinically stable COPD were studied, 35 of whom were recruited from the outpatient clinics at the Royal Infirmary, Edinburgh, 32 from the Department of Respiratory Medicine, University College, Dublin, and 28 from the Department of Pulmonology, Leiden University Medical Center, Leiden, The Netherlands. The characteristics of these patients are given in table 1. The diagnosis of COPD was made by a respiratory physician on the basis of current or ex-smoking and largely irreversible airways obstruction with <15% improvement in baseline forced expiratory volume in one second in response to inhaled β2 agonist. The clinical condition of the patients was stable, with no acute exacerbations of COPD in the month prior to entry into the study. Twenty five patients were current smokers and 70 were ex-smokers who had stopped smoking between six weeks and five years before their participation in the study.

At the time of the study 72 of the 95 patients had been receiving inhaled corticosteroid treatment for more than two years. All the patients were receiving inhaled bronchodilator therapy in the form of short acting β2 agonists and/or anticholinergic agents. Forced expiratory volume in one second (FEV1) and forced vital capacity (FVC) were measured with a bellows spirometer (Vitalograph Ltd, Buckingham, UK). FEV1 and FVC were expressed as a percentage of the predicted values for age, sex, and height based on the ERS guidelines, and FEV1 of >70% predicted was considered to be normal. The spirometric data from these patients are given in table 1.

Control Subjects

Healthy smokers/non-smokers

Eighty two healthy smokers recruited from hospital staff and the general population (32 from Edinburgh, 30 from Dublin and 20 from Leiden) participated in the study. Their characteristics and spirometric data are shown in table 1. Thirty one subjects were current smokers and 51 were ex-smokers who had stopped smoking six weeks to four years before their participation in the study. None was receiving any medications and specifically no inhaled bronchodilators or corticosteroids.

Thirty seven healthy non-smokers who had no history of lung disease and normal lung function were recruited from the hospital staff and used as control subjects.

The study was approved by the local ethical committee and all patients/subjects gave written informed consent.

Assays

For all of the assays described below, 10 ml of venous blood were withdrawn into a lithium heparin tube, centrifuged at 250g, the plasma removed and used for the following assays.

Plasma antioxidant capacity

Plasma antioxidant capacity was measured by the method of Rice-Evans and Miller. The Trolox equivalent antioxidant capacity

| Table 1 Mean (SD) characteristics of healthy non-smokers and smokers with and without COPD |
|----------------|----------------|----------------|
| Characteristics | Non-smokers | Smokers | COPD |
| M:F               | 21:16        | 53:29     | 55:40 |
| Age (years)      | 58 (8)       | 59 (7)    | 66 (9) |
| Smoking status   |              |           |      |
| Current smokers  | —            | 31        | 25    |
| Ex-smokers       | —            | 51        | 70    |
| Pack years       | 22 (6)       | 18 (4)    |       |
| FEV1 (% predicted)| 102 (18) | 89 (16)   | 45 (11) |
| FVC (% predicted)| 104 (15)    | 93 (17)   | 64 (14) |
| FEV1/FVC ratio   |              |           |       |
| (% predicted)    | 103 (16)     | 88 (18)   | 54 (10) |

FEV1 = forced expiratory volume in one second; FVC = forced vital capacity.
With men. \(^*p<0.01, \quad **p<0.001\)

**Table 3** Mean (SE) plasma antioxidant capacity and protein thiols in non-smokers, smokers, and patients with COPD

<table>
<thead>
<tr>
<th>Subjects</th>
<th>Antioxidant capacity (mM)</th>
<th>Protein thiols (mM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Healthy non-smokers (n = 31)</td>
<td>1.31 (0.11)</td>
<td>0.56 (0.06)</td>
</tr>
<tr>
<td>Healthy smokers (n = 82)</td>
<td>1.09 (0.04)**</td>
<td>0.39 (0.03)*</td>
</tr>
<tr>
<td>Current smokers (n = 51)</td>
<td>0.90 (0.05)**</td>
<td>0.42 (0.03)*</td>
</tr>
<tr>
<td>COPD (n = 95)</td>
<td>0.81 (0.03)**</td>
<td>0.40 (0.03)*</td>
</tr>
<tr>
<td>Ex-smokers (n = 25)</td>
<td>0.78 (0.05)**</td>
<td>0.43 (0.04)*</td>
</tr>
<tr>
<td>Ex-smokers (n = 70)</td>
<td>0.84 (0.02)**</td>
<td>0.38 (0.02)*</td>
</tr>
</tbody>
</table>

\(^*p<0.01, \quad **p<0.001\) compared with healthy non-smokers and non-significant (NS) compared with current smokers.

**Table 2** Mean (SE) plasma antioxidant capacity (TEAC) and protein thiols in healthy non-smokers, smokers, and patients with COPD

<table>
<thead>
<tr>
<th>Subjects</th>
<th>Antioxidant capacity (TEAC, mM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Healthy non-smokers (n = 31)</td>
<td>1.31 (0.11)</td>
</tr>
<tr>
<td>Healthy smokers (n = 82)</td>
<td>0.87 (0.04)**</td>
</tr>
<tr>
<td>Current smokers (n = 51)</td>
<td>0.90 (0.05)**</td>
</tr>
<tr>
<td>COPD (n = 95)</td>
<td>0.81 (0.03)**</td>
</tr>
<tr>
<td>Ex-smokers (n = 25)</td>
<td>0.78 (0.05)**</td>
</tr>
<tr>
<td>Ex-smokers (n = 70)</td>
<td>0.84 (0.02)**</td>
</tr>
</tbody>
</table>

**Discussion**

Several methods have been developed to assess the total antioxidant capacity of human serum or plasma. This is because of the difficulty in measuring each antioxidant component separ-
rately and the interactions between different antioxidant components in the serum or plasma. Using a method devised by Miller et al we have previously reported that the Trolox equivalent antioxidant capacity (TEAC) of the plasma was lower in smokers and in patients with exacerbations of COPD than in age matched healthy subjects. In this paper we have extended our study to a larger population of patients from three European centres (Edinburgh, Dublin, and Leiden) and confirmed our earlier observations of low antioxidant capacity in the plasma of smokers and patients with COPD. We provide further insights into the relationship between lung function and the antioxidant status in smokers and in patients with stable COPD.

A decreased plasma antioxidant capacity was observed in all the patients with COPD and in healthy smokers. We also showed that the decreased plasma antioxidant capacity was concomitant with a decrease in the levels of plasma protein sulphhydrils in smokers and in patients with COPD, suggesting a mechanism for the fall in TEAC levels. Several components of plasma contribute to plasma TEAC. Albumin, which has a sacrificial sulphhydril group, is thought to account for two thirds of the plasma TEAC. Although the levels of protein thiols were lower in smokers and patients with COPD, the plasma albumin levels remained stable. Many proteins such as ceruloplasmin, transferrin, and small antioxidant molecules such as non-protein thiols, vitamins C and E, and uric acid account for the remainder of the plasma TEAC. It has been reported that smoking is associated with a depletion of vitamins C and E in the blood. The lower plasma TEAC in patients with COPD and in chronic smokers could therefore result from depletion of such antioxidant molecules in addition to depletion of protein thiols.

A low antioxidant capacity in plasma suggests an increased oxidant burden in the blood. We and others have reported increased levels of superoxide anion release from circulating neutrophils and increased lipid peroxidation products in the plasma of smokers and patients with COPD, supporting the concept of systemic oxidative stress in these conditions. It is unclear, however, whether the oxidative stress that occurs in smokers is a direct effect of the oxidants/free radicals present in cigarette smoke or whether the endogenous inflammatory response is primarily responsible.

Smoking is known to produce systemic oxidative stress. We have previously shown that acute smokers have low plasma antioxidant defences compared with chronic smokers. In this study in a larger population we did not find significant differences in plasma TEAC and protein thiol levels between current smokers and ex-smokers, either in a healthy smoking population or in patients with COPD. However, the effects of acute smoking in these subjects and patients were not studied. This suggests that current smoking was not the main contributor to the reduction in levels of TEAC and protein thiols in patients with COPD. A possible explanation for the difference in this and our previous study may lie in the greater control over the immediate smoking history in our earlier study. Indeed, our observation in COPD is supported by the recent findings of Nowak et al who found no direct effects of cigarette smoking on the levels of lipid peroxidation products and H2O2 in the expired breath condensate of smokers and patients with COPD, suggesting that disease state rather than current smoking accounts for the systemic oxidative stress in patients with COPD.

We also did not find any sex differences in the levels of TEAC and protein sulphhydrils in healthy non-smokers, smokers, or in patients with COPD, nor was there any relationship with age in these subjects. A similar lack of sex dependent change in the glutathione concentrations has been reported in lymphocytes. However, a further study did show a decrease in glutathione concentrations and the activities of glutathione peroxidase and glutathione S-transferase with age. It is known from in vitro studies that corticosteroids inhibit the generation of ROS by neutrophils. However, we did not find evidence that treatment with steroids altered the plasma antioxidant capacity or protein thiol levels in patients with COPD. Similarly, in our previous studies we also did not find any significant differences in the levels of antioxidant capacity following treatment with corticosteroids in patients with acute exacerbations of COPD. Thus, our data showing the lack of differences in the plasma antioxidant capacity and protein thiols in these two groups could not be attributed to differences in treatment.

Recently there has been considerable interest in the association between dietary intake of antioxidants and measurements of systemic oxidative stress and lung function/symptoms in the general population and in smokers. The hypothesis is that a diet rich in antioxidants may help to protect the body against airway inflammation and lung damage caused by cigarette smoke and inhaled environmental pollutants. Thus, individual susceptibility to chronic airways disease may be determined by the ability of the body to deal with inhaled oxidants. However, we found that neither the plasma antioxidant capacity nor protein thiol levels correlated significantly with spirometric data in healthy non-smokers, smokers, or patients with COPD. Schunemann et al also found no significant correlation between serum antioxidant capacity measured as TEAC and FEV1 in a general population, whereas they found an inverse correlation between the levels of lipid peroxidation and lung function. Our data do not support the observation that higher levels of dietary vitamin C or β-carotene protect against the development of airways obstruction in healthy non-smoking
Oxidative stress and lung function in COPD

Nowak D, Antczak A, Krol M, Vurek A. Measurements of airway obstruction. Plasma would be likely to correlate with magnitude of oxidative stress occurring in smokers and patients with COPD. Those with COPD may make it unlikely that measurement of the antioxidant capacity in the plasma would be likely to correlate with measurements of airway obstruction.

A further reason for failing to find a significant correlation between plasma antioxidant capacity and lung function may relate to differences in the intake of dietary antioxidants since antioxidant vitamin supplementation in smokers leads to the inhibition of lipid peroxidation and to recovery in lung function and an increase in plasma antioxidant capacity. Our negative findings may simply be due to the relatively small numbers studied compared with these population studies. Furthermore, the variability of oxidative stress occurring in smokers and patients with COPD may make it unlikely that measurement of the antioxidant capacity in the plasma would be likely to correlate with measurements of airway obstruction.

In conclusion, this study confirms the presence of an oxidant/antioxidant imbalance systemically in smokers and in patients with COPD. The decrease in antioxidant capacity did not correlate with spirometric measurements of airway obstruction either in smokers or in patients with COPD.

This study was supported by the EUROMING EU BIOMED 2 Grant No. BMH4-CT96-0152 and the British Lung Foundation.

Is there any relationship between plasma antioxidant capacity and lung function in smokers and in patients with chronic obstructive pulmonary disease?

Irfan Rahman, Elzbieta Swarska, Michael Henry, Jan Stolk and William MacNee

Thorax 2000 55: 189-193
doi: 10.1136/thorax.55.3.189

Updated information and services can be found at:
http://thorax.bmj.com/content/55/3/189

These include:

References
This article cites 36 articles, 11 of which you can access for free at:
http://thorax.bmj.com/content/55/3/189#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

Health education (1223)
Smoking (1037)
Tobacco use (1039)
Airway biology (1100)
Lung function (773)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/